Mesenchymal stem cell-derived secretomes for therapeutic potential of premature infant diseases

Area of Science:

• Neonatal Medicine
• Regenerative Medicine
• Cell Biology

Background:

• Preterm birth is a global health issue with severe complications like PVL, BPD, NEC, and ROP.
• Existing treatments for preterm birth complications are limited, leading to high morbidity and mortality.
• Mesenchymal stem/stromal cells (MSCs) demonstrate therapeutic potential in preclinical models of these conditions.

Purpose of the Study:

• To review the paracrine mechanisms of MSC secretomes in treating preterm birth complications.
• To highlight the roles of MSC-conditioned media (CM) and extracellular vesicles (EVs) in MSC-based therapies.
• To provide insights for developing novel therapies for newborn medicine.

Main Methods:

• Review of preclinical studies and literature on MSC secretomes and paracrine actions.
• Analysis of MSC-conditioned media (CM) and extracellular vesicles (EVs) as therapeutic mediators.
• Focus on mechanisms relevant to periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), and retinopathy of prematurity (ROP).

Main Results:

• MSC secretomes exert therapeutic effects via paracrine signaling in response to tissue injury.
• MSC-conditioned media (CM) and extracellular vesicles (EVs) are key components of MSC-based therapies.
• These paracrine mechanisms are crucial for addressing pathologies associated with preterm birth.

Conclusions:

• MSC secretomes, particularly CM and EVs, offer a promising therapeutic strategy for preterm birth complications.
• Understanding MSC paracrine mechanisms provides new insights for neonatal medicine.
• Further research into MSC-based therapies could significantly improve outcomes for premature infants.